Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | IMvigor010: atezolizumab for UC

Thomas Powles • 15 May 2020
ASCO 2020
Bladder Cancer Genitourinary Cancer Antibodies Atezolizumab
IMvigor010

Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK, provides an overview of IMvigor010 (NCT02450331), a Phase III, open-label, randomized, multicenter study is to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with observation in participants with muscle-invasive urethelial carcinoma (UC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Thomas Powles

LITESPARK-005: HRQoL with belzutifan versus everolimus for advanced RCC
6:12
LITESPARK-005: HRQoL with belzutifan versus everolimus for advanced RCC
Brian Rini et al. • 31 Mar 2025
Key takeaways from ASCO 2024: advances in kidney cancer biomarkers and neoadjuvant therapy
1:00
Key takeaways from ASCO 2024: advances in kidney cancer biomarkers and neoadjuvant therapy
Thomas Powles • 1 Aug 2024
Exploring ctDNA in muscle-invasive bladder cancer: future applications and current limitations
1:17
Exploring ctDNA in muscle-invasive bladder cancer: future applications and current limitations
Thomas Powles • 1 Jun 2024
KEYNOTE-361: ctDNA as a biomarker in advanced urothelial carcinoma
5:04
KEYNOTE-361: ctDNA as a biomarker in advanced urothelial carcinoma
Thomas Powles • 1 Jun 2024

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals